top of page
Clinical Trial
Clemastine Treatment in Individuals With Williams Syndrome
The clinical trial investigates the safety and efficacy of a potential new treatment for Williams syndrome, targeting improved myelination.
Building on Prof. Barak's research, which highlighted the effectiveness of clemastine (an FDA-approved drug) in enhancing myelination and neurobiological features in a relevant mouse model, this study aims to assess safety and effectiveness in enhancing the quality of life for individuals with Williams syndrome. Special attention will be given to addressing social, motor, and cognitive abnormalities.
Location: Israel
Start date: January 2024
Estimated completion date: December 2025
bottom of page